{"preliminary_commentary":{"by_channel":{"bluesky_thread":50,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03989414\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT03989414","nct_id":"NCT03989414","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03989414. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Cohort A: CC-92480 with bortezomib and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort C: CC-92480 with carfilzomib and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort H: CC-92480 with elotuzumab and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort I: CC-92480 with isatuximab and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort D: CC-92480 with bortezomib and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort F: CC-92480 with carfilzomib and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort J: CC-92480 with elotuzumab and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort K: CC-92480 with isatuximab and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort G: CC-92480 with bortezomib and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Subcohort B1: CC-92480 with daratumumab and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Subcohort B2: CC-92480 with daratumumab and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Subcohort B3: CC-92480 with daratumumab and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Subcohort E1: CC-92480 with daratumumab and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Subcohort E2: CC-92480 with daratumumab and dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Subcohort E3: CC-92480 with daratumumab and dexamethasone","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":424,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"CC-92480","otherNames":["BMS-986348","mezigdomide"],"type":"DRUG"},{"name":"Bortezomib","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Daratumumab","otherNames":[],"type":"DRUG"},{"name":"Carfilzomib","otherNames":[],"type":"DRUG"},{"name":"Elotuzumab","otherNames":[],"type":"DRUG"},{"name":"Isatuximab","otherNames":[],"type":"DRUG"},{"name":"Carfilzomib","otherNames":[],"type":"DRUG"}],"last_update":"2024-11-29","lead_sponsor":"Celgene","official_title":"A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recommended Dose","timeFrame":"Up to approximately 3 years"},{"measure":"Recommended regimen as measured by dose-limiting toxicities","timeFrame":"Up to approximately 3 years"},{"measure":"Number of participants with Adverse Events (AEs)","timeFrame":"From first participant first visit until 28 days after the last subject discontinues study treatment, up to 5 years"},{"measure":"Overall response rate (ORR)","timeFrame":"Up to approximately 5 years"}],"references":[],"start_date":{"date":"2019-09-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)","url":"https://clinicaltrials.gov/study/NCT03989414"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03989414"}